Parkinson's disease
| 3 min read
A Phase 1 trial at Keck Medicine of USC is testing whether implanted iPSC-derived neurons can restore dopamine signaling and improve motor function.
| 3 min read
By combining human-derived data with AI-driven discovery, the partnership seeks to tackle Parkinson’s disease heterogeneity and improve target selection.
| 6 min read
New software and hardware tools that collect data while a person types can detect fine motor impairment — a possible sign of neurodegeneration.
| 4 min read
An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.
Available on Demand
From vascularized organoids to Parkinson's disease in a dish, scientists are pushing the boundaries of 3D cell research.
| 4 min read
Vertex-Enlaza autoimmune drugs, DNA-wrapped CRISPR, HHS staff demand Kennedy’s resignation, and more lead the news this week.
| 3 min read
The FDA approved Medtronic’s adaptive deep brain stimulation system, which delivers electrical stimulation in real time based on the brain’s state.
| 5 min read
From an executive order to lower drug prices to GLP-1 drug comparisons and a link between Parkinson’s disease and golf courses, it was a busy industry news week.
| 5 min read
The enzyme PGK1 sets the rate of cellular energy production and may be an ideal drug target when Parkinson’s disease neurons struggle to fuel themselves.
| 6 min read
Scores of neurons are already dead by the time Parkinson’s disease is usually diagnosed. Scientists aim to identify patients earlier and intervene before it’s too late.
